Chemomab Therapeutics (CMMB) Other Non-Current Assets (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Other Non-Current Assets of $211000.0 for Q4 2025, down 16.93% on a QoQ basis from $254000.0 in Q3 2025, and down 45.19% year-over-year from $385000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $211000.0 for Q4 2025.
- Quarterly Other Non-Current Assets fell 45.19% year-over-year to $211000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $211000.0 (down 45.19% YoY) and the FY2025 annual result came in at $211000.0, down 45.19% from the prior year.
- Other Non-Current Assets was $211000.0 for Q4 2025 at Chemomab Therapeutics, down from $254000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $952000.0 in Q3 2021 and bottomed at $4000.0 in Q1 2021.
- A 5-year average of $473789.5 and a median of $472000.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets sank 91.3% — and 2022, when it soared 2025.0%.
- Chemomab Therapeutics' Other Non-Current Assets stood at $908000.0 in 2021, then decreased by 14.54% to $776000.0 in 2022, then fell by 27.96% to $559000.0 in 2023, then tumbled by 31.13% to $385000.0 in 2024, then plunged by 45.19% to $211000.0 in 2025.
- Business Quant data shows CMMB's Other Non-Current Assets at $211000.0 in Q4 2025, $254000.0 in Q3 2025, and $298000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 211,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 298,000.00 |
| Mar 31, 2025 | 341,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Mar 31, 2024 | 516,000.00 |
| Dec 31, 2023 | 559,000.00 |
| Sep 30, 2023 | 603,000.00 |
| Jun 30, 2023 | 646,000.00 |
| Mar 31, 2023 | 690,000.00 |
| Sep 30, 2022 | 776,000.00 |
| Jun 30, 2022 | 821,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 908,000.00 |
| Sep 30, 2021 | 952,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Dec 31, 2020 | 53,000.00 |